FSD Pharma taps Charles Pollack Jr as chairman of its scientific advisory board

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) announced Thursday that it is tapping Charles V Pollack Jr as the new chairman of the company’s scientific advisory board.  

In this capacity, Dr Pollack will serve as a “strategic guide and resource” as FSD Pharma develops disruptive, science-based, cannabinoid therapeutics, said the company.

Headquartered in Toronto, FSD is focused on the development of indoor grown pharmaceutical grade cannabis and on the research and development of cannabinoid treatments for central nervous system disorders such as chronic pain and irritable bowel syndrome.

READ: FSD Pharma and Canntab Therapeutics forge pact with World Class Extractions to strike hemp deal

“Dr Pollack’s expertise and knowledge from the Lambert Center for the Study of Medicinal Cannabis and Hemp, an organization he founded at the Thomas Jefferson University in Philadelphia, will be very valuable in shaping the biopharmaceutical strategic direction of the company,” said FSD Pharma’s interim CEO Dr Raza Bokhari. “We look forward to gaining counsel from Dr Pollack on the assessment of various scientific and clinical opportunities as well as the development of our pipeline.”

Dr Charles Pollack is an international leader in emergency medicine and has been active in teaching and clinical research. He is the only physician to have received the American College of Emergency Physicians’ highest national awards in both teaching and research.

Dr Pollack’s research interests lie in the management of thrombosis, reversal of anticoagulation, infectious disease emergencies, and the treatment of pain.

Spearheading R&D around medicinal cannabinoids​

He founded the Lambert Center for the Study of Medicinal Cannabis and Hemp at Thomas Jefferson University, in Philadelphia in 2016. The center is the only comprehensive academic resource for education, research, and practice around the use of medicinal cannabinoids to be housed in an American university. He is also an editorial board member of the journal Cannabis and Cannabinoid Research.

Dr Pollack graduated summa cum laude from Emory University in 1980, with Bachelor’s degrees in history and chemistry and with a Master’s degree in the history of science and medicine. Dr Pollack earned his medical degree from Tulane University School of Medicine and is a member of Alpha Omega Alpha.

Dr Pollack has written 500 original research articles and abstracts, and serves on the editorial boards of several journals.

“I am pleased to chair the scientific advisory board and work with the FSD Pharma team to advance the company’s strategy in cannabinoid therapeutic programs,” said Dr Pollack. “FSD Pharma has an opportunity to explore a unique and exciting approach to a new class of compounds based on cannabinoid science, which will bring new therapies to indications of high unmet medical need.”

FSD Pharma, through its wholly-owned subsidiary FV Pharma Inc, holds an ACMPR license to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

It is transforming its large facility in Cobourg into the world’s largest hydroponic indoor cannabis production and processing facility, with multiple business units co-supporting each other, operating under a single roof to exploit economies of scale and operational efficiencies.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Story by ProactiveInvestors